Endothelial cell‐derived angiopoietin‐2 is a therapeutic target in treatment‐naive and bevacizumab‐resistant glioblastoma

Glioblastoma multiforme (GBM) is treated by surgical resection followed by radiochemotherapy. Bevacizumab is commonly deployed for anti‐angiogenic therapy of recurrent GBM; however, innate immune cells have been identified as instigators of resistance to bevacizumab treatment. We identified angiopoietin‐2 (Ang‐2) as a potential target in both naive and bevacizumab‐treated glioblastoma. Ang‐2 expression was absent in normal human brain endothelium, while the highest Ang‐2 levels were observed in bevacizumab‐treated GBM. In a murine GBM model, VEGF blockade resulted in endothelial upregulation of Ang‐2, whereas the combined inhibition of VEGF and Ang‐2 leads to extended survival, decreased vascular permeability, depletion of tumor‐associated macrophages, improved pericyte coverage, and increased numbers of intratumoral T lymphocytes. CD206+ (M2‐like) macrophages were identified as potential novel targets following anti‐angiogenic therapy. Our findings imply a novel role for endothelial cells in therapy resistance and identify endothelial cell/myeloid cell crosstalk mediated by Ang‐2 as a potential resistance mechanism. Therefore, combining VEGF blockade with inhibition of Ang‐2 may potentially overcome resistance to bevacizumab therapy.

[1]  I. Keklikoglou,et al.  Perivascular M2 Macrophages Stimulate Tumor Relapse after Chemotherapy. , 2015, Cancer research.

[2]  Y. Reiss,et al.  Angiopoietin‐2: a multifaceted cytokine that functions in both angiogenesis and inflammation , 2015, Annals of the New York Academy of Sciences.

[3]  R. Bourgon,et al.  Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  J. D. de Groot,et al.  Antiangiogenic Therapy for Glioblastoma: Current Status and Future Prospects , 2014, Clinical Cancer Research.

[5]  M. Dimopoulos,et al.  Profile of trebananib (AMG386) and its potential in the treatment of ovarian cancer , 2014, OncoTargets and therapy.

[6]  V. Kosma,et al.  Serum angiopoietin-2 and soluble VEGFR-2 levels predict malignancy of ovarian neoplasm and poor prognosis in epithelial ovarian cancer , 2014, BMC Cancer.

[7]  E. Butcher,et al.  Transcriptional programs of lymphoid tissue capillary and high endothelium reveal control mechanisms for lymphocyte homing , 2014, Nature Immunology.

[8]  I. Keklikoglou,et al.  Role of angiopoietin-2 in adaptive tumor resistance to VEGF signaling blockade. , 2014, Cell reports.

[9]  R. Vernhout,et al.  Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. , 2014, The Lancet. Oncology.

[10]  G. Zadeh,et al.  VEGF regulates region-specific localization of perivascular bone marrow-derived cells in glioblastoma. , 2014, Cancer research.

[11]  B. Monk,et al.  Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial. , 2014, The Lancet. Oncology.

[12]  J. Blay,et al.  Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. , 2014, Cancer cell.

[13]  G. Coukos,et al.  Tumor Endothelium FasL Establishes a Selective Immune Barrier Promoting Tolerance in Tumors , 2014, Nature Medicine.

[14]  K. Aldape,et al.  A randomized trial of bevacizumab for newly diagnosed glioblastoma. , 2014, The New England journal of medicine.

[15]  K. Hoang-Xuan,et al.  Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. , 2014, The New England journal of medicine.

[16]  H. Nakshatri,et al.  Angiopoietin‐2 mediates blood–brain barrier impairment and colonization of triple‐negative breast cancer cells in brain , 2014, The Journal of pathology.

[17]  Steffen Jung,et al.  On-site education of VEGF-recruited monocytes improves their performance as angiogenic and arteriogenic accessory cells , 2013, The Journal of experimental medicine.

[18]  D. Quail,et al.  Microenvironmental regulation of tumor progression and metastasis , 2014 .

[19]  Y. Kienast,et al.  Ang-2-VEGF-A CrossMab, a Novel Bispecific Human IgG1 Antibody Blocking VEGF-A and Ang-2 Functions Simultaneously, Mediates Potent Antitumor, Antiangiogenic, and Antimetastatic Efficacy , 2013, Clinical Cancer Research.

[20]  Christina S. Leslie,et al.  CSF-1R inhibition alters macrophage polarization and blocks glioma progression , 2013, Nature Medicine.

[21]  Zhaoshi Jiang,et al.  An interleukin-17–mediated paracrine network promotes tumor resistance to anti-angiogenic therapy , 2013, Nature Medicine.

[22]  Sonja Loges,et al.  Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer. , 2013, The Journal of clinical investigation.

[23]  Matthew J. Brauer,et al.  Identification and Analysis of In Vivo VEGF Downstream Markers Link VEGF Pathway Activity with Efficacy of Anti-VEGF Therapies , 2013, Clinical Cancer Research.

[24]  P. Saharinen,et al.  Angiopoietin signaling in the vasculature. , 2013, Experimental cell research.

[25]  P. Allavena,et al.  Tumor-associated macrophages: functional diversity, clinical significance, and open questions , 2013, Seminars in Immunopathology.

[26]  C. Lewis,et al.  Macrophage regulation of tumor responses to anticancer therapies. , 2013, Cancer cell.

[27]  H. Augustin,et al.  Angiopoietin-2: an attractive target for improved antiangiogenic tumor therapy. , 2013, Cancer research.

[28]  Y. Kienast,et al.  A Novel Angiopoietin-2 Selective Fully Human Antibody with Potent Anti-Tumoral and Anti-Angiogenic Efficacy and Superior Side Effect Profile Compared to Pan-Angiopoietin-1/-2 Inhibitors , 2013, PloS one.

[29]  R. Jain,et al.  Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy , 2012, Proceedings of the National Academy of Sciences.

[30]  R. Woods,et al.  MEDI3617, a human anti-angiopoietin 2 monoclonal antibody, inhibits angiogenesis and tumor growth in human tumor xenograft models. , 2012, International journal of oncology.

[31]  K. Alitalo,et al.  Effects of Angiopoietin-2-Blocking Antibody on Endothelial Cell–Cell Junctions and Lung Metastasis , 2012, Journal of the National Cancer Institute.

[32]  E. Chavakis,et al.  Angiopoietin-2 promotes myeloid cell infiltration in a β₂-integrin-dependent manner. , 2011, Blood.

[33]  P. Carmeliet,et al.  Molecular mechanisms and clinical applications of angiogenesis , 2011, Nature.

[34]  L. Naldini,et al.  Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. , 2011, Cancer cell.

[35]  K. Plate,et al.  Angiopoietin 2 Stimulates TIE2-Expressing Monocytes To Suppress T Cell Activation and To Promote Regulatory T Cell Expansion , 2011, The Journal of Immunology.

[36]  Janet Do,et al.  Specifically Targeting Angiopoietin-2 Inhibits Angiogenesis, Tie2-Expressing Monocyte Infiltration, and Tumor Growth , 2011, Clinical Cancer Research.

[37]  D. McDonald,et al.  Angiopoietin-2-driven vascular remodeling in airway inflammation. , 2010, The American journal of pathology.

[38]  K. Dietz,et al.  Spatio‐temporal deleted in colorectal cancer (DCC) and netrin‐1 expression in human foetal brain development , 2010, Neuropathology and applied neurobiology.

[39]  L. Nguyen,et al.  Context-Dependent Role of Angiopoietin-1 Inhibition in the Suppression of Angiogenesis and Tumor Growth: Implications for AMG 386, an Angiopoietin-1/2–Neutralizing Peptibody , 2010, Molecular Cancer Therapeutics.

[40]  D. Nam,et al.  Double antiangiogenic protein, DAAP, targeting VEGF-A and angiopoietins in tumor angiogenesis, metastasis, and vascular leakage. , 2010, Cancer cell.

[41]  K. Plate,et al.  Angiopoietin-2 regulates gene expression in TIE2-expressing monocytes and augments their inherent proangiogenic functions. , 2010, Cancer research.

[42]  Thijs J. Hagenbeek,et al.  PlGF Blockade Does Not Inhibit Angiogenesis during Primary Tumor Growth , 2010, Cell.

[43]  D. McDonald,et al.  Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth. , 2010, Cancer research.

[44]  S. Gabriel,et al.  Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. , 2010, Cancer cell.

[45]  Mohammad Tabrizi,et al.  A Human Monoclonal Anti-ANG2 Antibody Leads to Broad Antitumor Activity in Combination with VEGF Inhibitors and Chemotherapy Agents in Preclinical Models , 2010, Molecular Cancer Therapeutics.

[46]  P. Koumoutsakos,et al.  Tumorigenesis and Neoplastic Progression Contrasting Actions of Selective Inhibitors of Angiopoietin-1 and Angiopoietin-2 on the Normalization of Tumor Blood Vessels , 2009 .

[47]  P. Keegan,et al.  FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. , 2009, The oncologist.

[48]  Gavin Thurston,et al.  Control of vascular morphogenesis and homeostasis through the angiopoietin–Tie system , 2009, Nature Reviews Molecular Cell Biology.

[49]  D. Schadendorf,et al.  Angiopoietin-2 Levels Are Associated with Disease Progression in Metastatic Malignant Melanoma , 2009, Clinical Cancer Research.

[50]  Fabian Kiessling,et al.  Flt-1 signaling in macrophages promotes glioma growth in vivo. , 2008, Cancer research.

[51]  M. Giacca,et al.  Anti-PlGF Inhibits Growth of VEGF(R)-Inhibitor-Resistant Tumors without Affecting Healthy Vessels , 2007, Cell.

[52]  G. Fuh,et al.  Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells , 2007, Nature Biotechnology.

[53]  K. Plate,et al.  Angiopoietin-2 Impairs Revascularization After Limb Ischemia , 2007, Circulation research.

[54]  B. Scheithauer,et al.  The 2007 WHO classification of tumours of the central nervous system , 2007, Acta Neuropathologica.

[55]  K. Lee,et al.  Serum angiopoietin-2 as a clinical marker for lung cancer. , 2007, Chest.

[56]  Luigi Naldini,et al.  Identification of proangiogenic TIE2-expressing monocytes (TEMs) in human peripheral blood and cancer. , 2007, Blood.

[57]  Thomas D. Wu,et al.  Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. , 2006, Cancer cell.

[58]  H. Augustin,et al.  Angiopoietin-2 sensitizes endothelial cells to TNF-α and has a crucial role in the induction of inflammation , 2006, Nature Medicine.

[59]  Rinat Abramovitch,et al.  VEGF-Induced Adult Neovascularization: Recruitment, Retention, and Role of Accessory Cells , 2006, Cell.

[60]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[61]  P. Kleihues,et al.  Epidemiology and etiology of gliomas , 2005, Acta Neuropathologica.

[62]  R. Jain.  Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy , 2005, Science.

[63]  Lei Xu,et al.  Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. , 2004, Cancer cell.

[64]  Thomas Hartmann,et al.  Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. , 2004, Cancer cell.

[65]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[66]  G. Yancopoulos,et al.  VEGF-Trap: A VEGF blocker with potent antitumor effects , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[67]  G. Yancopoulos,et al.  In Situ Expression of Angiopoietins in Astrocytomas Identifies Angiopoietin-2 as an Early Marker of Tumor Angiogenesis , 1999, Experimental Neurology.

[68]  G. Yancopoulos,et al.  Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. , 1999, Science.

[69]  K. Plate,et al.  Cell type-specific expression of angiopoietin-1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis. , 1998, The American journal of pathology.

[70]  K. Plate,et al.  The Angiopoietin—Tie System: Common Signaling Pathways for Angiogenesis, Cancer, and Inflammation , 2015 .

[71]  K. Plate,et al.  Lack of evidence for PlGF mediating the tumor resistance after anti-angiogenic therapy in malignant gliomas , 2014, Journal of Neuro-Oncology.

[72]  Alastair H Kyle,et al.  Angiopoietin-2 functions as a Tie2 agonist in tumor models, where it limits the effects of VEGF inhibition. , 2013, Cancer research.

[73]  the original work is properly cited. , 2022 .